



(11) **EP 3 052 109 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
23.06.2021 Bulletin 2021/25

(45) Date of publication and mention
of the grant of the patent:
12.05.2021 Bulletin 2021/19

(21) Application number: **14850630.6**

(22) Date of filing: **02.10.2014**

(51) Int Cl.:
A61K 35/44 ^(2015.01) **A61P 35/00** ^(2006.01)
A61P 7/00 ^(2006.01) **A61P 3/00** ^(2006.01)
A61P 43/00 ^(2006.01) **A61K 35/51** ^(2015.01)
A61K 35/12 ^(2015.01) **A61K 35/50** ^(2015.01)
A61P 7/04 ^(2006.01) **A61P 7/06** ^(2006.01)
A61P 25/28 ^(2006.01) **A61P 35/02** ^(2006.01)
A61P 37/04 ^(2006.01) **A61P 37/06** ^(2006.01)

(86) International application number:
PCT/US2014/058774

(87) International publication number:
WO 2015/051088 (09.04.2015 Gazette 2015/14)

(54) **THERAPY WITH CELLS FROM HUMAN PLACENTA AND HEMATOPOIETIC CELLS**

THERAPIE MIT ZELLEN AUS MENSCHLICHER PLAZENTA UND HÄMATOPOETISCHEN ZELLEN

THÉRAPIE À CELLULES PROVENANT DE PLACENTA HUMAIN ET DES CELLULES

HÉMATOPOÏÉTIQUES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **03.10.2013 US 201361886648 P**
11.10.2013 US 201361890057 P

(43) Date of publication of application:
10.08.2016 Bulletin 2016/32

(73) Proprietor: **Celularity Inc.**
Florham Park, NJ 07932 (US)

(72) Inventors:
• **GURNEY, Jodi, P.**
Chicago, IL 60631 (US)
• **ZHANG, Xiaokui**
Martinsville, NJ 08836 (US)
• **HERB, Stacy**
Mountain Top, PA 18707 (US)
• **HARIRI, Robert, J.**
Warren, NJ 07059 (US)

(74) Representative: **Mewburn Ellis LLP**
Aurora Building
Counterslip
Bristol BS1 6BX (GB)

(56) References cited:
WO-A2-02/064755 **WO-A2-2007/089627**
US-A- 5 437 994 **US-A- 5 806 529**
US-B2- 8 329 468 **US-B2- 8 455 250**

- **ARIEN-ZAKAY H ET AL: "Tissue regeneration potential in human umbilical cord blood", BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 2, 1 June 2010 (2010-06-01), pages 291-303, XP027277895, ISSN: 1521-6926 [retrieved on 2010-06-01]**
- **LI CHANG DONG ET AL: "MESENCHYMAL STEM CELLS DERIVED FROM HUMAN PLACENTA SUPPRESS ALLOGENEIC UMBILICAL CORD BLOOD LYMPHOCYTE PROLIFERATION", CELL RESEARCH - XIBAO YANJIU, NATURE PUBLISHING GROUP, GB, CN, vol. 15, no. 7, 1 July 2005 (2005-07-01), pages 539-547, XP009080356, ISSN: 1001-0602, DOI: 10.1038/SJ.CR.7290323**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 052 109 B8

- SIRCHIA G & REBULLA P: "Placental/umbilical cord blood transplantation", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, IT, vol. 84, no. 8, 1 August 1999 (1999-08-01) , pages 738-747, XP002226904, ISSN: 0390-6078
- CHIN T W ET AL: "Enhanced interferon production and lymphokine-activated cytotoxicity of human placental cells", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 113, no. 1, 15 April 1988 (1988-04-15), pages 1-9, XP024003348, ISSN: 0008-8749, DOI: 10.1016/0008-8749(88)90001-9 [retrieved on 1988-04-15]